Cesarean Section

Women with an unplanned cesarean delivery had increased odds of developing postpartum depression and attending postpartum visits vs. those who delivered via planned cesarean or vaginally, researchers reported.

Women who used the Continuous Precision Medicine mobile application had a lower likelihood of misusing prescription opioids after cesarean section vs. nonusers, researchers reported in BMC Pregnancy and Childbirth.

Women with a kidney transplant may be more likely to have a cesarean section, labor-free delivery and vaginal complications than those without a transplant, according to data from an Australia-based study.

Cesarean deliveries declined statewide in California from 2015 to 2019 after efforts to support vaginal birth, including a marked reduction in cesarean deliveries before labor and those due to obstructed labor, researchers reported.

Pregnant women seeking an exercise routine that can potentially alleviate some pregnancy symptoms and improve delivery outcomes might be surprised to learn that resistance training, performed with guidance, could be an easy option.

An individualized opioid-prescription protocol with shared decision-making was associated with similar pain reports as fixed-quantity opioid prescriptions but with fewer prescribed opioids at hospital discharge following cesarean births.

About one in 11 women with cesarean deliveries at 34 weeks’ gestation or longer developed PTSD symptoms 2 months later, according to study results published in the American Journal of Obstetrics and Gynecology.

At 2 months postpartum, about one in 11 women with cesarean deliveries at 34 weeks’ gestation or longer developed PTSD symptoms, according to study results published in the American Journal of Obstetrics and Gynecology.

Worldwide, mean birth weight at term has increased by more than 7 g each year — a total of about 1 lb — since 1950, according to a systematic literature review published in the American Journal of Obstetrics and Gynecology.

Women reported a significantly lower frequency of moderate to severe menopausal vasomotor symptoms while taking elinzanetant vs. placebo, according to the results of a phase 3 trial.